Aurinia Pharmaceuticals 3Q 2026: Revenue $83.7M, Net income $31.7M, EPS $0.23— 10-Q Summary
Aurinia Pharmaceuticals reported 3Q 2026 revenue of $83.7M, up 13.9% YoY, and net income of $31.7M, up 0.5%. EPS remained at $0.23. LUPKYNIS sales rose 12% in the quarter, and the company launched a Phase 4 study for the drug.
How this was made
The 30-second read
Why it matters
The earnings release introduces new quantitative data that can shift analyst estimates and investor sentiment for AUPH.
Market read
First‑time earnings disclosure for a micro‑cap biotech, offering fresh data for short‑term trading decisions.
What to watch
Phase‑4 PRESERVE study enrollment risk and upcoming R&D spend may weigh on cash flow.
Background
The article is an AI‑generated summary of Aurinia's SEC 10‑Q filing, providing key financial and pipeline updates.
Ticker impact
Aurinia Pharmaceuticals filed its Q3 2026 10‑Q reporting $83.7M revenue and $0.23 EPS, the first public disclosure of these results.
likely slight upward pressure as the market prices in the revenue growth and phase‑4 study launch
First‑time earnings numbers provide new data; modest top‑line growth and unchanged EPS suggest limited but positive re‑rating potential.
Market effects
Biotech sector may see slight uplift as Aurinia's lupus nephritis product gains traction.
U.S. biotech investors could adjust exposure to small‑cap pharma stocks.
Limited; impact confined to niche biotech investors.
Counterpoint
Flat EPS despite revenue growth could signal margin pressure, suggesting a short‑term pullback.
Key entities
- companyAurinia Pharmaceuticals
Biopharmaceutical company focused on lupus nephritis treatments.
- partnerOtsuka
Provides manufacturing services generating royalty revenue for Aurinia.
